Pharmaron Beijing's (HKG:3759, SHE:300759) wholly owned unit, Pharmaron Shaoxing Pharmaceutical, has passed a pre-approval inspection by the US Food and Drug Administration, confirming compliance with current good manufacturing practices, a Monday Hong Kong bourse filing said.

The inspection, conducted between May 29 and June 4, covered multiple GMP systems, including quality, production, equipment, packaging, and laboratory controls.

Shares of the firm were down over 1% in Tuesday morning trade.